Thursday, November 03, 2016 8:57:00 PM
The DLBCL pt who experienced progression-free interval of 161 days is getting .05 mg/kg which is only 25% of the selected dose.
Manageable, dose-dependent thrombocytopenia was likely due to increased phagocytic clearance of platelets.
Macrophage-associated cytokines, including MIP-1a and MIP-1ß, increased during the 4 hrs after infusion
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM